Un abonnement à JoVE est nécessaire pour voir ce contenu. Connectez-vous ou commencez votre essai gratuit.
1Research Service,VA Western New York Healthcare System, 2Department of Ophthalmology, (Ross Eye Institute), Jacobs School of Medicine and Biomedical Sciences,University at Buffalo- SUNY, 3Pharmacology/Toxicology, Jacobs School of Medicine and Biomedical Sciences,University at Buffalo- SUNY, 4Physiology/Biophysics, Jacobs School of Medicine and Biomedical Sciences,University at Buffalo- SUNY, 5Neuroscience Program, Jacobs School of Medicine and Biomedical Sciences,University at Buffalo- SUNY, 6The RNA Institute,University at Buffalo- SUNY, 7The SUNY Eye Institute
Chapitres
- 00:04Titre
- 00:45Subretinal Injection
- 02:37Injection Site and Subretinal Bleb Mapping
- 04:03High Resolution Spectral-Domain Optical Coherence Tomography (HR-SD-OCT) Outer Retinal Degeneration Evaluation
- 07:47Results: Representative Outer Retinal Change Quantification and Post-Subretinal Injection 3D Mapping
- 08:54Conclusion
Aquí nos muestran un nuevo enfoque al uso de tomografía de coherencia óptica de dominio espectral de alta resolución (HR-SD-OCT) para facilitar la presentación de los agentes de terapia génica en el espacio subretinal, evaluar su cobertura areal y caracterizan la vitalidad del fotorreceptor.
Tags
Ultrahigh ResolutionMouseOptical Coherence TomographyIntraocular InjectionRetinal Gene TherapySubretinal InjectionVector DeliveryTherapeutic Agent ToxicityMinimally InvasiveReproducibleReal-time ObservationRetinal ImagingProptosisScleral DepressionRetinal Pigment EpitheliumSubretinal SpaceInjection OutcomesOCT Imaging
